Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension by Beyer, Swantje et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2006
Long-term experience with oral or inhaled vasodilator combination therapy
in patients with pulmonary hypertension
Beyer, Swantje; Speich, Rudolf; Fischler, Manuel; Maggiorini, Marco; Ulrich, Silvia
Abstract: BACKGROUND: Disease progression in pulmonary hypertension (PH) is common despite
standard vasodilator monotherapy with iloprost, bosentan or sildenafil. OBJECTIVE: To investigate
if the combination of these non-invasively applicable treatments is an effective option to address the
multiple pathophysiological mechanisms present in PH. METHODS: We analysed the clinical course of
23 patients with PH, diagnosed as idiopathic (n = 15), chronic thromboembolic (n = 4), and associated
with collagen vascular disease (n = 4), receiving combination vasodilator therapy at our institution.
RESULTS: Vasodilator therapy before combination therapy consisted of inhaled iloprost (I; n = 12), or
oral bosentan (B; n = 6) at a mean duration of 19 +/- 3 months. The combination therapy added was
B (n = 8), sildenafil (S; n = 6) or I (n = 4) and in five patients, combination therapy was given from
the beginning (3x BS, 1x IS, 1x IBS). Under combination therapy, the 6-minute walk distance (6MWD)
increased significantly by 46.7 +/- 24.8 m (p = 0.02) after three months, and after six months it was
still 38.3 +/- 28.3 m (p = 0.17) longer than before combination therapy. Respective changes in the Borg
Scale and the NYHA functional class were -1.05 +/- 0.49 (p = 0.014) and -0.42 +/- 0.19 (p = 0.02) after
three months and -0.21 +/- 0.65 (p = 0.61) and -0.38 +/- 0.29 (p = 0.26) after six months. Only minor
side effects were reported. CONCLUSION: Combination vasodilator therapy in severe PH is safe and
well tolerated. It significantly improves exercise capacity and stabilises the functional class in patients
with severe PH deteriorating under single-agent therapy.
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-75180
Published Version
Originally published at:
Beyer, Swantje; Speich, Rudolf; Fischler, Manuel; Maggiorini, Marco; Ulrich, Silvia (2006). Long-term
experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension.
Swiss Medical Weekly, 136(7-8):114-118.
Long-term experience with oral or inhaled
vasodilator combination therapy in patients
with pulmonary hypertension
Swantje Beyer, Rudolf Speich, Manuel Fischler, Marco Maggiorini, Silvia Ulrich
Department of Internal Medicine, University Hospital Zurich, Switzerland
Background: Disease progression in pulmonary
hypertension (PH) is common despite standard
vasodilator monotherapy with iloprost, bosentan
or sildenafil. 
Objective: To investigate if the combination of
these non-invasively applicable treatments is an
effective option to address the multiple pathophys-
iological mechanisms present in PH.
Methods: We analysed the clinical course of 23
patients with PH, diagnosed as idiopathic (n = 15),
chronic thromboembolic (n = 4), and associated
with collagen vascular disease (n = 4), receiving
combination vasodilator therapy at our institution. 
Results: Vasodilator therapy before combina-
tion therapy consisted of inhaled iloprost (I; n =
12), or oral bosentan (B; n = 6) at a mean duration
of 19 ± 3 months. The combination therapy added
was B (n = 8), sildenafil (S; n = 6) or I (n = 4) and
in five patients, combination therapy was given
from the beginning (3x BS, 1x IS, 1x IBS). Under
combination therapy, the 6-minute walk distance
(6MWD) increased significantly by 46.7 ± 24.8 m
(p = 0.02) after three months, and after six months
it was still 38.3 ± 28.3 m (p = 0.17) longer than
before combination therapy. Respective changes 
in the Borg Scale and the NYHA functional class
were –1.05 ± 0.49 (p = 0.014) and –0.42 ± 0.19 
(p = 0.02) after three months and –0.21 ± 0.65
(p = 0.61) and –0.38 ± 0.29 (p = 0.26) after six
months. Only minor side effects were reported.
Conclusion: Combination vasodilator therapy
in severe PH is safe and well tolerated. It signifi-
cantly improves exercise capacity and stabilises the
functional class in patients with severe PH deteri-
orating under single-agent therapy. 
Key words: pulmonary hypertension; vasodilator
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Severe pulmonary hypertension (PH) is a pro-
gressive disease with a poor prognosis that ulti-
mately leads to right ventricular failure and death.
Although therapeutic options continue to evolve,
the treatment of patients with severe PH remains
a challenge [1]. Continuous intravenous adminis-
tration of prostacyclins has been shown to improve
haemodynamics, exercise tolerance and survival
[2–4]. To obviate the substantial risks, incon-
veniences and costs associated with continuous 
intravenous administration, stable prostacyclin
analogues for inhaled, oral and subcutaneous ap-
plication and novel oral substances with different
action mechanisms such as endothelin receptor an-
tagonists (bosentan) and phosphodiesterase-5 in-
hibitors (sildenafil) have been introduced [1, 5–8].
Despite the fact that all these substances have pos-
itive effects on PH, they do not provide a cure, so
that in many patients the disease progresses despite
therapy. The optimal management of patients de-
teriorating under oral or inhaled single therapy is
not yet known. Currently, the combination of two
non-invasive treatments to circumvent continuous
intravenous prostacyclin is being discussed as a po-
tential new therapeutic approach [1, 5, 9]. There-
fore, we analysed the long-term performance and
outcome of patients with severe PH treated with
vasodilator combination therapy at our institution.
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Patient selection
Between July 2002 and October 2004, 23 patients
with PH diagnosed as pulmonary arterial hypertension 
(n = 15 idiopathic, n = 4 associated with collagen vascular
disease) and chronic thromboembolic PH (n = 4) receiv-
ing vasodilator combination therapy at our institution
were included in the study. All patients provided written
informed consent. Patients’ characteristics before combi-
nation therapy are shown in table 1. Patients were consid-
ered for combination vasodilator therapy when they either
deteriorated under vasodilator monotherapy or were too
ill for monotherapy at baseline, and, therefore, were con-
sidered to need non-invasive vasodilator combination
therapy. Patients under monotherapy were included when
at least two of the following criteria were fulfilled: 1)
subjective impairment, 2) deterioration in 6-min walk
distance of more than 20%, 3) clinical signs of right heart
failure despite optimisation of diuretic therapy, 4) recur-
rent syncopes. Patients, in whom vasodilator combination
therapy was started immediately from the beginning, ful-
filled at least one of the following criteria: 1) 6MWD
below 150 m, 2) NYHA functional class IV, 3) cardiac
index less than 2 l/min/m2, 4) mixed venous oxygen satu-
ration below 50% and non-willingness to undergo or con-
traindication to continuous intravenous iloprost therapy. 
Vasodilator treatment
The treatment consisted of inhaled iloprost (I), oral
bosentan (B), oral sildenafil (S) and their combinations [1].
For inhalation of iloprost (Ilomedin®, Schering AG,
Berlin, Germany) the recommended special inhalation
device Optineb® (Nebu-Tec AG, Elsenfelden, Germany)
was used to obtain iloprost particles at a mean diameter of
3 mm, which are known to reach the alveoli and remain
there for some time without being exhaled immediately.
Inhaled iloprost was started at a daily total dose of 25 mg
and slowly increased to the target daily dose of 100 µg
divided into five to six single inhalations of about five
minutes. Oral bosentan (Tracleer®, Actelion AG, Baden,
Switzerland) was started at a dose of 62.5 mg bid and in-
creased to the target dose of 125 mg bid after one month;
initially, the liver enzymes were monitored fortnightly,
then monthly as recommended. Sildenafil (Viagra®, Pfizer,
Zurich, Switzerland) was started at a dose of 12.5 mg tid
and increased fortnightly to the target dose of 50 mg tid. 
Follow-up and prospective assessments
All patients were closely followed up for therapeutic
effect, tolerance, side effects and signs of clinical deterio-
ration at our institution. The NYHA functional class was
assessed using the modified WHO-criteria [10], the
6MWD test was performed as recommended [11] and
supplemented with the Borg’s rating of perceived exertion
scale obtained at the end of the 6MWD test. Hereby, a
scale from 1–10 was used, with one signifying none and
ten maximal perceived exhaustion [12]. All measures were
assessed prospectively at baseline, at three and at six
months of combination therapy. 
Retrospective assessments
The records of study patients already under
monotherapy were reviewed for the duration of mono-
therapy, 6MWD, Borg Scale and NYHA functional class
at the beginning of vasodilator therapy and three and six
months thereafter. Additionally, the patient records 
were reviewed for self-assessed quality of life using the
Minnesota Living with Heart Failure Questionnaire
(MLHF-q) [10, 13, 14], a 21-item instrument previously
validated for PH patients at our clinic [15]. With the
MLHF-q patients assess how much the disease impacts
their physical, socio-economic and psychological aspects
of daily life from 0 (not at all) to 5 (very much). Scores on
the total instrument range from 0 to 105, with higher
scores representing lower quality of life. The first eight
questions relate primarily to physical functioning (physi-
cal subscore), whereas the last five are more about emo-
tional aspects (emotional subscore); the remaining ques-
tions relate to general aspects.
Patients’ survival
We compared survival of the present cohort, treated
with a strategy to switch to vasodilator combination ther-
apy in case of clinical worsening or to start immediate
combination therapy in case of high-risk baseline values,
with a historical cohort of PH patients included in the
American National Institute of Health Registry [16]. 
Statistics
All baseline data and graphic illustrations are given as
the mean and standard error of mean (). The Wilcoxon
Signed Rank Test was used to assess significant differences
(with two-sided p value) in the 6MWD, Borg Scale and
NYHA functional class. The standard life table method
was used for analysis of survival (SPSS version 12.0, Soft-
ware GmbH, Munich, Germany). A p <0.05 was consid-
ered significant. 
Methods
Results
Study population and baseline characteristics
The characteristics of the present patient pop-
ulation are shown in table 1.The mean duration of
previous vasodilator monotherapy with inhaled
iloprost (12 patients) or oral bosentan (6 patients)
was 19 (3) months. The combination therapy
added was B (n = 8), S (n = 6), and I (n = 4). Pa-
tients starting primarily with combination therapy
were given B and S (n = 3), I and B (n = 1), and all
three I, B, and S (n = 1). 
Retrospective analysis of performance 
during vasodilator monotherapy
During vasodilator monotherapy, the 6MWD
decreased by 35 (28) m (from 368 (31) to 334 (33),
p = 0.22) after an initial increase during the first 
6 months (figure 1), the Borg Scale significantly 
increased by 1.7 (0.6) (p = 0.03), and the NYHA
functional class significantly increased by 0.72
(0.21) (p = 0.007) (figure 2). From nine patients
under initial monotherapy complete MLHF-q
were available at baseline and before combination
therapy, the mean total score, physical subscore
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and emotional subscore increased by 10.3, 3.1 and
2 points, respectively. Haemodynamic data ob-
tained by right heart catheterisation could be re-
trieved from 12 out of the 18 patients, the mean
values during vasodilator monotherapy changed 
as follows: mean pulmonary artery pressure 
+4.9 mm Hg, pulmonary vascular resistance +147
dyn*s*m–5, cardiac index –0.1 ml/min/m–2, mixed
venous oxygen saturation –2.1%. The right 
ventricular above right atrial pressure calculated
from the tricuspidal regurgitation jet assessed 
by transthoracic echocardiography increased by
4.1 mm Hg. 
Analysis of performance during the 
six months prospective observational period
under vasodilator combination therapy
During vasodilator combination therapy, 
the overall 6MWD significantly increased by 47
(25) m (p = 0.02) after three months, and after 
six months, it was still 38 (28) m (p = 0.17) higher 
than before combination therapy (see figure 1 for
performance of individual patients). Respective
changes in the Borg ratings and NYHA functional
class were –1,0 (0.5) (p = 0.014) and –0.4 (0.2) (p =
0.02) at three months and –0.21 (0.65) (p = 0.61)
and –0.38 (0.29) (p = 0.26) at six months. Nine 
patients, all belonging to the group which was ini-
tially treated with monotherapy, returned MLHF-
q after the observational period with vasodilatator
combination therapy, the mean total score, physi-
cal subscore and emotional subscore declined by
7.6, 2.5 and 3.8 points, respectively. Hereby, the
decline in the emotional subscore reached statisti-
cally significance (p = 0.048).
Additional follow up and comparison 
of survival
Mean predicted survival for the present study
cohort according to the NIH formula (National
Institute of Health) [16] is calculated at 71% after
one, at 59% after two and at 51% after three years.
We followed up 22, 18 and 13 of the 23 patients of
the present cohort for one, two and three years, 
respectively. From the 22 patients followed up dur-
ing the first year, one patient died 8 months after
start of combination therapy due to disease pro-
gression (scleroderma), all other patients survived
(percentage of survivals of our cohort and the
NIH-cohort is shown in figure 4). Pulmonary
haemodynamics assessed 10 (4) months after onset
of combination therapy by right heart catheter-
isation (7 patients) and echocardiography (12 pa-
tients) showed the following respective changes:
mean pulmonary artery pressure –12 mm Hg, 
pulmonary vascular resistance –326 dyn*s*m–5,
cardiac index +0.6 ml/min/m–2, mixed venous oxy-
gen saturation –5.5% and echocardiographical
right ventricular/right atrial pressure –12 mm Hg.
Adverse events
The combination therapy was well tolerated
by all patients, none of them stopped the combi-
nation therapy, and none of the patients died dur-
ing the six-months study period. Reported side
effects were comparable between therapies. They
were only minor and consisted of dizziness (5 pa-
tients, 3 ib, 1 is, 1 ibs), flush (3 patients, 2 bs, 1 ib)
and headache (5 patients, 2 ib, 2 is, 1 bs), agitation
and sleeplessness (1 patient, ib) and minimal
peripheral oedema (3 patients, 2ib, 1 is), and the
therapy was not changed because of side effects.
One patient received lung transplantation at seven
month of combination therapy and was not evalu-
ated thereafter.
Discussion
This prospective observational study indicates
that combination of oral or inhaled vasodilator
therapy improves dyspnoea, exercise capacity and
Borg scale in severely ill patients with advanced
PH. In addition, survival of these patients might
be improved.
All patients in the present series had advanced
PH before onset of combination therapy con-
firmed by pulmonary haemodynamics, clinical as-
sessments and 6MWD (table 1). Patients treated
with second-line combination therapy had previ-
ously received standard, non-invasive vasodilator
first-line therapy with oral bosentan or inhaled ilo-
prost [6, 17] as recommended. Sildenafil was not
used as first-line therapy in this study, as results of
its beneficial effect on PH were published after
study initiation [7, 8]. Although in most patients,
the first-line therapy resulted in clinical improve-
Age 50 (3)
Sex females/males 14/9
NYHA functional class II/III/IV 1/4/18
Body mass index 25 (1.2)
6-minute walk distance (m) 330 (33)
Borg dyspnoea scale 6 (0.5)
Mean pulmonary arterial pressure (mm Hg) 50 (4)
Pulmonary vascular resistance (dynes*s*cm–5) 868 (112)
Cardiac index (l*min–1*m–2) 2.4 (0.2)
Mixed venous oxygen saturation (%) 62 (3)
Right ventricular/atrial pressure in echocardiography 70 (26)
Initial therapy bosentan/inhaled iloprost/none 6/12/5
Time on monotherapy until combination therapy 19 (3)
(months)
NYHA: New York Heart Association; data are given as mean 
and standard error of mean ()
Table 1
Patients’ characteris-
tics and haemody-
namics before onset
of combination
therapy.
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ment and increase in exercise tolerance (figure
1–3), this effect did not last. After an average
period of one and a half year these relatively young
patients showed clinical deterioration with a
marked decline in 6MWD (figure 1), higher rat-
ings of perceived exertion on the Borg Scale and
higher NYHA class (figure 2 and 3). The unfortu-
nate clinical reality is that even with novel target
treatments available for PH, a number of patients
deteriorates after initial improvement. Those pa-
tients usually have a dismal prognosis and will
eventually die from their underlying disease with-
out aggressive therapy [1, 5, 16]. Until recently, the
only valuable therapeutic alternative for this group
of patients was continuous intravenous prosta-
cyclin therapy [2, 4] or lung transplantation. How-
ever, continuous intravenous prostacyclin therapy
is inconvenient for the patients, and it bears a 
considerable risk of catheter-related diseases (in-
fections, thrombosis) and of rebound PH follow-
ing accidental discontinuation. The most recent
World Symposium on PH therefore postulated
that combination of preferably non-invasive va-
sodilator treatment might be an alternative to con-
tinuous intravenous therapy [1]. Although only a
few non-randomised observational studies about
vasodilator combination therapy in PH have been
published to date, the available data are promising
[9, 18–21]. In line with this, we found a significant
improvement of performance after three months
in our collective. The sustained response after six
months together with the comparatively beneficial
survival and preliminary haemodynamic follow-up
data are encouraging. However, a temporarily van-
ishing or even non-response might nonetheless 
be expected for some patients. Our cohort study
emphasises the effect of vasodilator combination
therapy on the care of severely ill PH patients,
especially on those deteriorating under monother-
apy. Moreover, vasodilator combination therapy
seems to be a highly effective first-line therapy for
patients in NYHA class IV, as seen in the five pa-
tients of the present cohort, who were given com-
bination therapy from the beginning. In four of the
five patients, combination therapy was started at
the intensive care unit. All of them improved con-
siderably and left the hospital walking. Combina-
tion therapy was well tolerated by all patients and
proved to be efficient in this “negatively” selected
subgroup of patients with very severe and progres-
sive disease. In addition to the significant improve-
ment in exercise capacity, exhaustion and dyspnoea
functional class (figure 1–3) we also found an 
improvement in the self-assessed quality of life
score in the patients who returned the MLHF-q.
However, due to the small patient number, only
the improvement of the emotional subscore was
statistically significant. 
Our strategy of combining vasodilator therapy
in patients either presenting with advanced disease
with dismal prognosis at baseline or patients who
deteriorate under monotherapy seems to be justi-
fied also by the considerable improvement in
survival in our study population compared with the
predicted survival in the NIH-cohort (figure 4)
[16]. However, these results have to be interpreted
with caution because the present series is quite
small and there have been 14 years of medical ad-
vancement since the results from the NIH-cohort
study by Alonzo et al. were published. Nonethe-
less, we believe, with respect to the pronounced
differences in the predicted and the observed sur-
vival curves, that the strategy including vasodilator
combination therapy might be highly effective in
patients with advanced PH.
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Figure 1
Change in six-minute
walk distance. CT =
combination therapy,
mo = months, 
th = therapy. Every
line shows the course
of a single patient.
Black lines are used 
for patients with ini-
tial monotherapy, red
lines for patients with
CT from the begin-
ning. Patients with
IPAH are represented
by plain lines,
patients CTEPH by
dotted lines and
patients with PH
associated with colla-
gen vascular disease
by dashed lines. 
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Figure 2
Change in Borg Scale
ratings. CT = combi-
nation therapy, mo =
months, th = therapy.
Every line shows the
course of a single
patient. Black lines
are used for patients
with initial monother-
apy, red lines for
patients with CT 
from the beginning.
Patients with IPAH
are represented by
plain lines, patients
CTEPH by dotted
lines and patients
with PH associated
with collagen vascu-
lar disease by dashed
lines. 
Figure 3 
Course of NYHA
class under first
mono- and combina-
tion therapy. CT =
combination therapy,
mo = months, th =
therapy. Lines show
course of patients
NYHA class over
time. Thickness of
line represents
number of patients
(0.5 pts/per patient).
Patients with initial
CT are depicted 
in red.
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Obviously, this observational study has several
inherent limitations: there was no control group,
the patient population was small and the overall ob-
servation time was rather short. In addition, treat-
ment with bosentan, inhaled iloprost and sildenafil
was not part of a formal study protocol, and the pa-
tients had only one right heart catheter examina-
tion, so that haemodynamic follow-up data were
not available. Although invasive data might be of
value, it is accepted good clinical practice to make
therapeutic decisions mainly relying on the pa-
tients’ functional classification, the 6MWD and the
overall clinical judgment [1, 18, 22, 23]. 
Our study population consisted of high-risk
patients, who were rapidly deteriorating under
standard vasodilator therapy and needed immedi-
ate access to new therapies. This high-risk cohort
showed a favourable clinical response to oral or 
inhaled vasodilator combination therapy. Further
adequately powered randomised controlled trials
on the efficacy of non-invasive combination ther-
apy are warranted, our preliminary data show that
under close monitoring by an experienced team,
non-invasively applicable combination therapy is
an effective and save therapeutic option for se-
verely ill PH patients. 
In summary, our data provide preliminary but
highly encouraging evidence that combination va-
sodilator therapy in severe PH is safe, effective and
convenient. 
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Figure 4
Survival of present
cohort compared
with predicted sur-
vival (NIH-cohort,
Alonzo et al. [16]).
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